Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Lille
Clinical trial register · France

Clinical Trials in Lille, 2026

Every study on the ClinicalTrials.gov registry that lists a site in France and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 9722 matching records held by the registry are in this view. Synced 29 Oct 2026, 03:20 UTC
9722
Studies in scope
all four open statuses
6047
Recruiting now
open to new participants
1031
Lead sponsors
across recruiting studies
Top sites
Paris 2823 Lyon 1395 Bordeaux 1389 Marseille 1291 Lille 1281
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
University Hospital, Lille138 Janssen Research & Development, LLC43 Hoffmann-La Roche38 AstraZeneca36 Hospices Civils de Lyon34
Site location
Paris2823 Lyon1395 Bordeaux1389 Marseille1291 Lille1281
All 809 locations
Target enrolment
to

Trials with a site in Lille

1281 of 9722 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in France
Start
Recruiting
Centre Oscar Lambret
Not applicable
20
Lille
2027-09
Not yet open
University Hospital, Lille
Observational
1,600
Lille
2027-03
Not yet open
To Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients
NCT07898774C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative, Glomerulonephritis (IC-MPGN), Kidney Transplantation
DrugPegcetacoplan
Swedish Orphan Biovitrum
Phase 3
30
Strasbourg, Toulouse, Montpellier, Lille, Paris, Lyon
2027-01-21
Not yet open
Central Hospital, Nancy, France
Not applicable
800
Argenteuil, Clermont-Ferrand, Épagny, Lille, Mulhouse, Nancy, Paris, Poitiers
2027-01-10
Not yet open
University Hospital, Lille
Phase 2
96
Lille
2027-01-06
Not yet open
Hospices Civils de Lyon
Observational
100
Angers, Caen, Clichy, Dijon, La Tronche, Lille, Lyon, Nantes
2027-01-01
Not yet open
Dexmedetomidine for Invasive Ventilation In the NEOnate
NCT07493785Invasive Ventilation, Infant Pain, Infant Discomfort, Infant Neurodevelopment
DrugDexmedetomidine
Centre Hospitalier Intercommunal Creteil
Phase 2/3
246
Brest, Créteil, Grenoble, Lille, Limoges, Nantes, Nice, Paris
2027-01-01
Not yet open
Institut Cancerologie de l'Ouest
Not applicable
144
Angers, Brest, La Roche-sur-Yon, Le Mans, Lille, Lyon, Saint-Nazaire
2027-01
Not yet open
Remote Ischemic Postconditioning in Septic Shock
NCT07273942Adult Patients With Septic Shock Admitted in Intensive Care Unit
Hospices Civils de Lyon
Not applicable
720
Besançon, Bourg-en-Bresse, Clermont-Ferrand, Créteil, Dijon, La Tronche, Le Kremlin-Bicêtre, Lille
2027-01
Not yet open
University Hospital, Lille
Observational
400
Béziers, Bordeaux, Brest, Caen, Lille, Lyon, Marseille, Nice
2027-01
Not yet open
What is the Role of the Exposome in Pulmonary Hypertension
NCT07172334Pulmonary Arterial Hypertension (PAH), Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Poitiers University Hospital
Observational
150
Bordeaux, Brest, Le Kremlin-Bicêtre, Lille, Lyon, Nancy, Poitiers, Saint-Etienne
2027-01
Not yet open
Assistance Publique Hopitaux De Marseille
Phase 4
224
Amiens, Avignon, Besançon, Bordeaux, Clermont-Ferrand, Lille, Lyon, Marseille
2027-01
Not yet open
Endoscopic Treatment
NCT07727824Stenoses, Dyspnea
University Hospital, Toulouse
Not applicable
96
Le Plessis-Robinson, Lille, Limoges, Strasbourg, Suresnes, Toulouse
2027-01
Not yet open
The Lymphoma Academic Research Organisation
Phase 2
44
Angers, Caen, Chambéry, Clermont-Ferrand, La Roche-sur-Yon, Le Mans, Lille, Lyon
2026-12-31
Not yet open
Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy
NCT07814001Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Refractory Large B-cell Lymphoma (LBCL), Refractory T-cell/Histiocyte-rich Large B-cell Lymphoma, Refractory Transformed Follicular Lymphoma
DrugsEpcoritamab·Lenalidomide
The Lymphoma Academic Research Organisation
Phase 2
55
Créteil, Dijon, Lille, Limoges, Lyon, Marseille, Montpellier, Nantes
2026-12
Not yet open
University Hospital, Tours
Phase 3
266
Angers, Caen, Lille, Marseille, Nantes, Strasbourg, Tours
2026-11-15
Not yet open
Assistance Publique - Hôpitaux de Paris
Phase 2
30
Bron, Lille, Rennes
2026-11-01
Not yet open
University Hospital, Bordeaux
Not applicable
60
Bron, Caen, Lille, Limoges, Montpellier, Nîmes, Paris, Pessac
2026-11-01
Not yet open
Individualized Dose of Fibrinogen Following Cardiopulmonary Bypass
NCT07425600Fibrinogen Deficiency in Complex Cardiac Surgery
DrugBlood samples for PK
Centre Hospitalier Universitaire de Saint Etienne
Observational
150
Lille, Saint-Etienne
2026-11-01
Not yet open
Best Salvage Treatment for High-risk Relapsing Prostate Cancer (PEACE-9 - ESCALATE-RT)
NCT07782112Prostatic Neoplasms, Biochemical Recurrence, Oligometastatic Prostate Cancer
DrugEnzalutamide
Ente Ospedaliero Cantonale, Bellinzona
Phase 3
140
Bordeaux, Lille, Saint-Etienne, Saint-Herblain, Villejuif
2026-11
Not yet open
A Minute for my Kidneys
NCT07869849Chronic Kidney Diseases
GCS Ramsay Santé pour l'Enseignement et la Recherche
Not applicable
312
Lille
2026-11
Not yet open
University Hospital, Angers
Phase 3
50
Angers, Besançon, Bordeaux, Bron, Dijon, La Tronche, Le Kremlin-Bicêtre, Lille
2026-11
Not yet open
Wockhardt
Phase 3
324
Lille, Paris, Argenteuil
2026-10-28
Not yet open
Novo Nordisk A/S
Phase 3
8,500
Chambray-lès-Tours, Le Coudray, Lille, Massy, Paris, Pessac, Poitiers, Quint-Fonsegrives
2026-10-26
Recruiting
Novo Nordisk A/S
Phase 3
84
Bron, Le Kremlin-Bicêtre, Lille, Nantes
2026-10-16
Not yet open
University Hospital, Lille
Observational
17
Lille
2026-10-15
Not yet open
Centre Francois Baclesse
Not applicable
130
Caen, Bayeux, Lille, Rouen, Saint-Lô
2026-10-01
Recruiting
ODSSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY
NCT07545512Myocardial Infarction (MI), Sudden Cardiac Death Due to Cardiac Arrhythmia
University Hospital, Clermont-Ferrand
Not applicable
400
Amiens, Brest, Caen, Clermont-Ferrand, Lille, Lyon, Nancy, Nantes
2026-10-01
Not yet open
Perioperative Yoga Therapy and Endometriosis Surgery
NCT07765680Endometriosis, Chronic Pain, Impairment of Quality of Life
University Hospital, Lille
Not applicable
188
Amiens, Calais, Lille
2026-10-01
Not yet open
University Hospital, Strasbourg, France
Phase 1/2
89
Bordeaux, Lille, Lyon, Marseille, Nancy, Paris, Strasbourg, Toulouse
2026-10
Not yet open
Centre Oscar Lambret
Not applicable
493
Lille
2026-10
Recruiting
AstraZeneca
Phase 3
750
Lille, Nantes, Paris, Toulouse
2026-09-24
Recruiting
Boehringer Ingelheim
Phase 3
466
Angers, Bobigny, Bron, Caen, La Tronche, Lille, Marseille, Nice
2026-09-17
Recruiting
Daiichi Sankyo
Phase 1/2
220
Caen, Dijon, Lille, Lyon, Marseille, Montpellier, Nice, Nîmes
2026-09-17
Recruiting
Takeda
Phase 3
324
Nice, Pierre-Bénite, Strasbourg, Marseille, Brest, Pessac, Lille, Paris
2026-09-10
Not yet open
Superior Mesenteric Artery First Versus Standard Approach in Pancreaticoduodenectomy
NCT07547033Pancreatic Adenocarcinoma, Pancreatic Head Cancer
Assistance Publique - Hôpitaux de Paris
Not applicable
150
Amiens, Angers, Besançon, Bordeaux, Clermont-Ferrand, Dijon, Lille, Limoges
2026-09-01
Not yet open
University Hospital, Rouen
Not applicable
206
Dijon, Lille, Nancy, Nantes, Paris, Rouen, Toulouse
2026-09-01
Not yet open
Fondation Hôpital Saint-Joseph
Not applicable
2,400
Angers, Bobigny, Bordeaux, Clermont-Ferrand, Dijon, Le Plessis-Robinson, Lille, Lyon
2026-09-01
Not yet open
University Hospital, Toulouse
Phase 3
724
Bordeaux, Grenoble, Lille, Limoges, Marseille, Montpellier, Nantes, Paris
2026-09-01
Not yet open
University Hospital, Lille
Observational
100
Lille
2026-09
Not yet open
Lung Disease and FLNA Mutations
NCT07592637Emphysema
University Hospital, Lille
Not applicable
70
Lille
2026-09
Not yet open
French Innovative Leukemia Organisation
Phase 2
60
Angers, Bayonne, Besançon, Clamart, Créteil, Grenoble, Lille, Limoges
2026-09
Not yet open
Centre Leon Berard
Phase 1/2
50
Bourg-en-Bresse, Clermont-Ferrand, Grenoble, Lille, Lyon, Marseille, Saint-Priest-en-Jarez, Toulouse
2026-09
Not yet open
SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer
NCT07241273Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Cancers, Oropharyngeal Carcinoma, Head and Neck
UNICANCER
Not applicable
128
Brest, Caen, Dijon, Le Havre, Lille, Montpellier, Paris, Rouen
2026-09
Not yet open
University Hospital, Lille
Phase 2
30
Lille
2026-09
Not yet open
UNICANCER
Phase 2
130
Auxerre, Beuvry, Caen, Calais, Compiègne, Coudekerque-Branche, Lille, Lyon
2026-08-31
Not yet open
iVascular S.L.U.
Not applicable
45
Bordeaux, Lille
2026-08-31
Recruiting
Kardigan, Inc.
Phase 3
332
Chambray-lès-Tours, Lille, Paris, Rennes
2026-08-26
Recruiting
Novo Nordisk A/S
Phase 3
450
Caen, Le Coudray, Lille, Vénissieux
2026-08-12
Recruiting
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
NCT07746895C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
DrugPegcetacoplan
Swedish Orphan Biovitrum
Phase 4
150
Bordeaux, Bron, Créteil, Lille, Marseille, Montpellier, Nantes, Paris
2026-08-05
Recruiting
University Hospital, Limoges
Not applicable
187
Bordeaux, Le Chesnay, Lille, Limoges, Poissy, Poitiers, Rennes
2026-08-05
Not yet open
Lupin Ltd.
Observational
100
Angers, Lille, Marseille, Nantes, Paris, Toulouse
2026-08-03
Not yet open
Intravenous Lidocaine for Hepatectomy
NCT07590830Hepatectomy
Rennes University Hospital
Phase 4
312
Clermont-Ferrand, La Roche-sur-Yon, Le Coudray, Lille, Lyon, Nice, Paris, Rennes
2026-08-01
Recruiting
CLE-PAD : Prevalence of PAD in Patients With Surgically Lumbar Spinal Stenosis
NCT07469020PAD - Peripheral Arterial Disease, Lumbar Spinal Stenosis, Lower Limb Arterial Disease
Rennes University Hospital
Not applicable
49
Lille, Paris, Rennes
2026-08
Recruiting
Assessment of the Long-term Efficacy of Moderately Hypofractionated Neoadjuvant Radiotherapy Soft Tissue Sarcoma in the Limbs or Trunk Wall
NCT07507773Soft Tissue Sarcoma Adult, Soft Tissue Sarcoma (Excluding GIST), Soft Tissue Sarcoma of the Trunk and Extremities, Soft Tissue Sarcoma of the Limb
Centre Oscar Lambret
Phase 2
135
Lille
2026-07-21
Not yet open
Assistance Publique - Hôpitaux de Paris
Observational
25
Lille, Lyon, Paris
2026-07-15
Recruiting
Fondation Ildys
Observational
343
Caen, Giens, Grenoble, Lille, Lyon, Montpellier, Paris, Reims
2026-07-09
Recruiting
Pediatric Congenital Adrenal Hyperplasia Management: Regret and Long-term Outcomes
NCT07781267Classic Congenital Adrenal Hyperplasia, 21-Hydroxylase Deficiency
University Hospital, Lille
Observational
40
Lille
2026-07-08
Recruiting
Centre Hospitalier Universitaire de Saint Etienne
Not applicable
70
Angers, Clermont-Ferrand, Grenoble, Lille, Limoges, Lyon, Marseille, Nancy
2026-07-06
Recruiting
Lidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease
NCT07274254Vaso-Occlusive Pain Episode in Sickle Cell Disease
DrugLidocain
Nantes University Hospital
Phase 3
104
Bordeaux, Lille, Marseille, Nantes, Orléans, Paris, Poitiers, Rouen
2026-07-03
Not yet open
University Hospital, Rouen
Not applicable
350
Amiens, Lille, Rouen, Suresnes
2026-07-01
Not yet open
UNICANCER
Phase 2/3
160
Angers, Bordeaux, Brest, Caen, Clermont-Ferrand, Dijon, Grenoble, Lille
2026-07
Recruiting
Poitiers University Hospital
Not applicable
2,600
Angers, Grenoble, Le Coudray, Lille, Lyon, Marseille, Mont-de-Marsan, Nantes
2026-06-29
Recruiting
University Hospital, Lille
Observational
306
Lille
2026-06-27
Recruiting
AstraZeneca
Phase 3
750
Lille, Nantes, Paris, Poitiers, Toulouse
2026-06-26
Recruiting
Hopital Foch
Phase 2
36
Besançon, Bordeaux, Caen, Lille, Paris, Suresnes
2026-06-24
Recruiting
Hoffmann-La Roche
Phase 3
380
Nantes, Lille, Pierre-Benite (Lyon), Poitiers, Toulouse
2026-06-23
Recruiting
A Study of ARC-02 in B-cell NHL
NCT07691606B-cell Non Hodgkin Lymphoma
DrugRituximab
Taiho Oncology, Inc.
Phase 1
140
Créteil, Lille, Lyon, Nantes, Villejuif
2026-06-22
Recruiting
PAravertebral CaTheter Versus Epidural Analgesia in Totally Minimally Invasive Esophagectomies
NCT07434739Esophageal Cancer, Esophagectomy, Multimodal Analgesia, Minimally Invasive Surgery
University Hospital, Lille
Not applicable
506
Lille
2026-06-22
Not yet open
University Hospital, Lille
Observational
74
Lille
2026-06-15
Recruiting
Centre Hospitalier Universitaire de Nice
Observational
50
Nice, Angers, Boulogne-sur-Mer, Créteil, Garches, Grenoble, Lille, Limoges
2026-06-15
Recruiting
Pharming Technologies B.V.
Phase 2
140
Angers, Bordeaux, Lille, Nantes, Nice, Strasbourg
2026-06-12
Recruiting
University Hospital, Montpellier
Phase 2
6
Lille, Montpellier, Paris, Rouen
2026-06-11
Recruiting
EXPLOration of Processes Involved in Dissociative Identity Disorder (DID)
NCT07663890Dissociative Identity Disorder (DID)
Lille University
Observational
60
Carvin, Chambray-lès-Tours, Lille, Tours
2026-06-04
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals
Phase 3
300
Caen, Créteil, Lille, Marseille, Nantes, Paris, Rennes, Toulouse
2026-06-03
Not yet open
University Hospital, Antwerp
Not applicable
266
Lille
2026-06-01
Not yet open
University Hospital, Lille
Not applicable
180
Lille
2026-06-01
Not yet open
The MAI-FOIE Cohort
NCT07594990Autoimmune Liver Diseases, Immunological Mechanisms
Nantes University Hospital
Observational
800
Angers, Brest, Clichy, La Roche-sur-Yon, Lille, Lyon, Nantes, Paris
2026-06-01
Not yet open
Gustave Roussy, Cancer Campus, Grand Paris
Observational
1,100
Caen, Clermont-Ferrand, Clichy, Dijon, Lille, Lyon, Marseille, Paris
2026-06
Not yet open
Assistance Publique - Hôpitaux de Paris
Observational
108
Bron, Lille, Montpellier, Nancy, Nantes, Paris
2026-06
Not yet open
University Hospital, Lille
Observational
115
Lille
2026-06
Not yet open
iVascular S.L.U.
Not applicable
160
Bordeaux, Brest, Lille, Nancy, Paris, Strasbourg
2026-05-31
Recruiting
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
NCT07101328Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Eli Lilly and Company
Phase 1
215
Lille, Paris
2026-05-28
Recruiting
Janssen Research & Development, LLC
Phase 3
644
Amiens, Besançon, Clichy, Le Kremlin-Bicêtre, Lille, Montpellier, Nantes, Nice
2026-05-23
Recruiting
University Hospital, Lille
Phase 3
477
Lille
2026-05-22
Recruiting
Janssen Research & Development, LLC
Phase 3
460
Besançon, Clichy, Le Kremlin-Bicêtre, Lille, Montpellier, Nantes, Nice, Pessac
2026-05-22
Recruiting
University Hospital, Lille
Phase 2
192
Lille
2026-05-19
Recruiting
Hoffmann-La Roche
Phase 3
138
Le Kremlin-Bicêtre, Bron, Lille
2026-05-15
Recruiting
Ipsen
Phase 3
350
Lille, Lyon, Montpellier, Nantes, Paris, Toulouse, Villejuif
2026-05-14
Recruiting
University Hospital, Rouen
Phase 2
120
Amiens, Caen, Lille, Rouen
2026-05-12
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 3
1,020
Bordeaux, Lille, Saint Priest En Jarez, Lyon, Villejuif, Paris
2026-05-06
Recruiting
Cohort of Patients With Chronic Myelomonocytic Leukemia
NCT07512882Leukemia, Myelomonocytic Leukemia, Chronic
Gustave Roussy, Cancer Campus, Grand Paris
Observational
5,000
Amiens, Angers, Antony, Bobigny, Corbeil-Essonnes, Grenoble, Le Kremlin-Bicêtre, Lille
2026-05-05
Recruiting
Initiatives Bronchopneumopathie Chronique Obstructive (BPCO)
Observational
500
Bordeaux, Lille, Nancy, Paris, Reims, Saint-Etienne
2026-05-01
Not yet open
University Hospital, Lille
Not applicable
526
Lille
2026-05
Recruiting
Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers
NCT06958224Breast Cancer, Liver Cancer, Pancreatic Ductal Adenocarcinoma
University Hospital, Lille
Not applicable
360
Lille
2026-04-29
Recruiting
Poitiers University Hospital
Not applicable
578
Amiens, Brest, Caen, Grenoble, Lille, Marseille, Nantes, Paris
2026-04-29
Recruiting
Hoffmann-La Roche
Phase 3
360
Le Kremlin-Bicêtre, Bron, Lille, Paris
2026-04-27
Active, closed
Novo Nordisk A/S
Phase 3
606
Clermont-Ferrand, La Tronche, Le Creusot, Lille, Poitiers
2026-04-21
Recruiting
Janssen-Cilag Ltd.
Observational
200
Lille
2026-04-17
Recruiting
Medtronic
Observational
970
Lille
2026-04-17
Recruiting
University Hospital, Tours
Observational
10,000
Angers, Lille, Toulouse, Tours
2026-04-09
Recruiting
Incyte Corporation
Phase 3
588
Brest, Dijon, Lille, Lyon, Marseille, Montpellier, Paris, Pessac
2026-04-09
Recruiting
University Hospital, Toulouse
Observational
120
Bordeaux, Caen, Lille, Lyon, Marseille, Paris, Rennes
2026-04-07
Recruiting
Hoffmann-La Roche
Phase 2
80
Lille, Lyon, Marseille, Montpellier, Toulouse
2026-04-07
Not yet open
Assistance Publique - Hôpitaux de Paris
Observational
350
Bordeaux, Clamart, Clermont-Ferrand, Le Kremlin-Bicêtre, Lille, Lyon, Martigues, Nancy
2026-04-01
Not yet open
University Hospital, Tours
Phase 4
200
Amiens, Bordeaux, Chambray-lès-Tours, Créteil, Dijon, La Tronche, Le Mans, Lille
2026-04-01
Not yet open
University Hospital, Grenoble
Not applicable
540
Angers, Clermont-Ferrand, Clichy, Grenoble, Le Kremlin-Bicêtre, Lille, Lyon, Marseille
2026-04
Not yet open
Hospices Civils de Lyon
Phase 2
122
Amiens, Bobigny, Caen, Clichy, Créteil, Dijon, Grenoble, Lille
2026-04
Not yet open
Totally Versus Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer
NCT07408999Resecable Esophageal or Gastroesophageal Junction Cancer
University Hospital, Lille
Not applicable
327
Lille
2026-03-31
Recruiting
Bristol-Myers Squibb
Phase 1/2
474
Lille, Villejuif, Boredeaux
2026-03-26
Recruiting
Anesthesia Management in Endovascular Therapy for Ischemic Stroke - 2
NCT07235514Ischemic Stroke, Anterior Cerebral Circulation, General Anesthesia, Procedural Sedation
University Hospital, Clermont-Ferrand
Not applicable
958
Angers, Brest, Clermont-Ferrand, Lille, Lyon, Marseille, Montpellier, Nantes
2026-03-24
Recruiting
University Hospital, Tours
Observational
149
Angers, Bordeaux, Brest, Dijon, Grenoble, Lille, Lyon, Marseille
2026-03-23
Recruiting
SymBio Pharmaceuticals
Phase 3
180
Bordeaux, Lille, Nancy, Nantes, Paris, Rennes, Strasbourg
2026-03-17
Recruiting
SYSNAV
Observational
30
Lille
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 3
850
Bordeaux, Lyon Cedex08, Dijon, Montpellier, Saint-Herblain, Toulouse, Lille, Villejuif
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 2/3
690
Lyon Cedex08, Brest, Lille, Nantes, Poitiers, Marseille, Paris
2026-03-13
Recruiting
Assistance Publique - Hôpitaux de Paris
Not applicable
298
Clermont-Ferrand, Créteil, Lille, Paris, Rennes, Strasbourg, Toulouse, Vandœuvre-lès-Nancy
2026-03-13
Recruiting
Bristol-Myers Squibb
Phase 3
750
Nice, Pessac, Lille, Montpellier, La Tronche, Saint-Herblain, Toulouse, Villefranche-sur-Saône
2026-03-12
Recruiting
University Hospital, Lille
Not applicable
66
Lille, Tours, Amiens, Brest, Bron, Caen, Chambéry, Clermont-Ferrand
2026-03-10
Recruiting
University Hospital, Lille
Observational
1,126
Lille
2026-03-02
Not yet open
University Hospital, Caen
Not applicable
270
Amiens, Caen, Cherbourg, Le Havre, Lille, Rouen
2026-03
Not yet open
IHU Strasbourg
Observational
300
Aix-en-Provence, Besançon, Échirolles, Lille, Lyon, Montpellier, Saint-Etienne, Sète
2026-03
Recruiting
Mirum Pharmaceuticals, Inc.
Phase 2/3
120
Bordeaux, Clermont-Ferrand, Clichy, Créteil, Grenoble, Lille, Limoges, Lyon
2026-02-26
Recruiting
Center Eugene Marquis
Phase 2
80
Grenoble, Lille, Marseille, Montpellier, Nice, Rennes
2026-02-25
Recruiting
Circadian Rhythm Deregulation in Patients With CAPS
NCT06544018Cryopyrin Associated Periodic Syndrome, Familial Cold Urticaria, Muckle-Wells Syndrome, CINCA Syndrome
DrugBlood sampling
Hospices Civils de Lyon
Not applicable
30
Bron, Lille, Lyon, Paris
2026-02-25
Recruiting
AstraZeneca
Phase 3
508
Lille, Nantes, Paris, Pierre-Bénite, Poitiers, Toulouse
2026-02-23
Recruiting
Development of a Prediction Score for the Occurrence of Death or Lung Transplantation in Patients With Emphysema Secondary to Alpha-1-anti-tripsin Deficiency
NCT07715617Alpha-1-antitrypsin Deficiency, Emphysema, Artificial Intelligence (AI), Predictive Learning Models
University Hospital, Bordeaux
Observational
230
Bron, Lille, Paris, Pessac
2026-02-16
Recruiting
iVascular S.L.U.
Not applicable
165
Bordeaux, Brest, Lille, Marseille, Nîmes, Toulouse, Villeneuve-d'Ascq
2026-02-16
Recruiting
Kardigan, Inc.
Phase 2/3
332
Chambray-lès-Tours, Lille, Paris, Rennes
2026-02-13
Recruiting
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
NCT07201922Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
80
Bron, Lille, Paris, Rennes, Toulouse
2026-02-10
Recruiting
Nantes University Hospital
Phase 3
222
Aix-en-Provence, Angers, Brest, Lille, Lyon, Nantes, Rennes
2026-02-09
Recruiting
Janssen Research & Development, LLC
Phase 3
400
Lille, Lyon, Nancy, Nantes, Paris, Pessac, Poitiers, Toulouse
2026-02-04
Recruiting
University Hospital, Lille
Not applicable
94
Lille
2026-02-03
Recruiting
Prilenia
Phase 3
500
Lille, Marseille, Nice, Paris, Tours
2026-02-01
Recruiting
Johnson & Johnson Enterprise Innovation Inc.
Phase 1
45
Brest, La Tronche, Lille, Marseille, Rouen, Villejuif
2026-01-26
Recruiting
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
NCT07159841Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 2/3
153
Angers, Le Kremlin-Bicêtre, Lille, Marseille, Paris
2026-01-22
Recruiting
BeOne Medicines
Phase 3
500
Bordeaux, ClermontFerrand, Le Mans, Lille, Lyon, Montpellier, Toulouse
2026-01-22
Recruiting
Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma
NCT06254248Liver Transplant, Hepatocellular Carcinoma Recurrent, Systemic Treatment
Assistance Publique - Hôpitaux de Paris
Phase 2
50
Clichy, Créteil, Lille, Lyon, Montpellier, Paris, Rennes, Strasbourg
2026-01-22
Recruiting
Janssen Research & Development, LLC
Phase 1
340
Lille, Paris, Pierre-Bénite, Toulouse
2026-01-20
Recruiting
Sanofi
Phase 3
751
Amiens, Besançon, Créteil, La Tronche, Lille, Marseille, Nantes, Nice
2026-01-16
Recruiting
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
NCT07220616Hematological Malignancies, B-cell Non-Hodgkin Lymphoma
Daiichi Sankyo
Phase 1/2
420
Lille, Pierre-Bénite, Villejuif
2026-01-16
Recruiting
Central Hospital, Nancy, France
Phase 3
60
Besançon, Bordeaux, Brest, Caen, Clermont-Ferrand, Colmar, Grenoble, Lille
2026-01-15
Not yet open
Luspatercept in Patients Affected With Rare Inherited Anemias
NCT07331818Hereditary Red Blood Cell Disorder (Disorder)
DrugReblozyl
EuroBloodNet Association
Phase 2
45
Lille, Montpellier, Paris, Pessac
2026-01-15
Not yet open
Institut du Cancer de Montpellier - Val d'Aurelle
Not applicable
120
Dijon, Montpellier, Rennes, Saint-Herblain, Lille, Villeurbanne, Rouen, Avignon
2026-01-15
Recruiting
Novartis Pharmaceuticals
Phase 1/2
181
Créteil, Lille, Nantes
2026-01-13
Recruiting
Eli Lilly and Company
Phase 3
150
Bron, Corbeil-Essonnes, Lille, Marseille, Paris, Toulouse
2026-01-12
Recruiting
Pharmaceutical Management in Targeted Radioligand Therapy
NCT07389512Cancer, Thyroid Cancer, Metastatic Prostate Cancer, Neuroendocrine Tumor Carcinoid
Hospices Civils de Lyon
Observational
600
Bron, Dijon, Lille
2026-01-09
Recruiting
AbbVie
Phase 2/3
680
Epagny Metz Tessy, Dunkirk, Lille, Montpellier, Tours, Vannes, Pessac, Poitiers
2026-01-08
Recruiting
Rennes University Hospital
Phase 3
532
Angers, Bordeaux, Brest, Caen, Dijon, Grenoble, Lille, Marseille
2026-01-07
By invitation
Medtronic
Observational
2,000
Chambray-lès-Tours, La Tronche, Lille, Montpellier, Pessac, Rennes, Rouen, Toulouse
2026-01-07
Recruiting
Insmed Incorporated
Phase 3
344
Nice, Marseille, Angers, Lille, Saint Priest En Jarez, Le Kremlin-Bicêtre, Poitiers, Brest
2026-01-07
Not yet open
University Hospital, Bordeaux
Observational
450
Amiens, Bois-Guillaume, Bordeaux, Caen, Créteil, Grenoble, Lille, Lyon
2026-01
Recruiting
Bristol-Myers Squibb
Phase 2/3
990
Pessac, Besançon, Toulouse, Rouen, Suresnes, Saint-Herblain, Lorient, Lille
2025-12-31
Recruiting
Sanofi
Phase 2
144
Lille, Nantes, Paris, Rouen
2025-12-29
Recruiting
Nantes University Hospital
Observational
50
Angers, Annecy, Avignon, La Roche-sur-Yon, Lille, Nantes, Orléans, Poitiers
2025-12-19
Recruiting
Janssen Research & Development, LLC
Phase 3
800
Bordeaux, Clermont-Ferrand, Lille, Lyon, Nîmes, Paris, Rennes, Villejuif
2025-12-19
Active, closed
Safety, Performance, and Clinical Benefit of Pacing the Left Bundle Branch Area - Post-Market Clinical Follow-up
NCT07209852Bradycardia, Atrioventricular Block, Sinus Node Dysfunction, Bundle-Branch Block
Boston Scientific Corporation
Observational
140
Lille, Paris
2025-12-19
Recruiting
Effects of Spinal Anesthesia on the Fetal Autonomic Nervous System
NCT07333729Obstetrics: Elective Caesarean Delivery
University Hospital, Lille
Not applicable
50
Lille
2025-12-17
Recruiting
University Hospital, Lille
Not applicable
130
Lille
2025-12-17
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
DrugCetuximab
Revolution Medicines, Inc.
Phase 3
500
Lille, Rennes, Villejuif, Marseille
2025-12-15
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Angers, Bordeaux, Brest, Caen, Lille, Lyon Cedex08, Marseille, Nîmes
2025-12-12
Recruiting
Assistance Publique - Hôpitaux de Paris
Observational
1,000
Angers, Bordeaux, Brest, Lille, Lyon, Marseille, Paris, Strasbourg
2025-12-11
Recruiting
Pfizer
Phase 3
800
Villejuif, Brest, Dijon, Lille, Paris, Poitiers, Créteil
2025-12-11
Recruiting
AbbVie
Phase 2/3
490
Marseille, Brest, Lille, Montpellier, Paris
2025-12-10
Recruiting
Cystinosis and Mitochondrial Metabolism
NCT07319091Cystinosis, Native Kidney
Hospices Civils de Lyon
Not applicable
25
Bron, Lille, Lyon, Marseille, Montpellier, Paris, Vandœuvre-lès-Nancy
2025-12-08
Recruiting
GlaxoSmithKline
Phase 3
450
Angers, Bordeaux, Lille, Lyon, Marseille, Saint-Herblain, Toulouse, Villejuif
2025-12-03
Recruiting
Daiichi Sankyo
Phase 1
60
Lille, Lyon
2025-12-03
Recruiting
Janssen Research & Development, LLC
Phase 3
500
Avignon, Le Mans, Lille, Marseille, Paris, Rouen, Saint-Herblain, Villejuif
2025-12-03
Recruiting
Bristol-Myers Squibb
Phase 3
650
Toulouse, Villeurbanne, Lille, Limoges, Montpellier, Paris, Strasbourg
2025-12-02
Not yet open
University Hospital, Toulouse
Not applicable
178
Bordeaux, Lille, Marseille, Montpellier, Paris, Quint-Fonsegrives, Toulouse
2025-12-01
Active, closed
Cochlear
Not applicable
36
La Tronche, Lille
2025-12-01
Active, closed
Institut Cancerologie de l'Ouest
Observational
22,000
Lille, Lyon, Paris, Saint-Herblain
2025-12-01
Recruiting
Centre Hospitalier Universitaire de Nice
Observational
30
Nice, Bron, Garches, Le Kremlin-Bicêtre, Lille, Marseille, Strasbourg, Toulouse
2025-11-26
Recruiting
Syndax Pharmaceuticals
Phase 3
468
Nice, Strasbourg, Marseille, Caen, Rouen, Limoges, Angers, Lille
2025-11-25
Recruiting
Momelotinib in VEXAS Syndrome
NCT07098936VEXAS Syndome, Myelo Dysplastic Syndrome
Groupe Francophone des Myelodysplasies
Phase 2
57
Angers, Clermont-Ferrand, Lille, Nantes, Paris, Pessac, Pierre-Bénite, Rennes
2025-11-25
Recruiting
Hoffmann-La Roche
Phase 3
900
Marseille, Bron, Clermont-Ferrand, Créteil, La Tronche, Lille, Limoges, Montpellier
2025-11-24
Recruiting
Reasoning Enrichment With Feedback From IA in NEphrology Trial
NCT07352475Diagnosis, Clinical Decision-making, Artificial Intelligence (AI) in Diagnosis, Decision Support Systems, Clinical
University Hospital, Lille
Not applicable
100
Lille
2025-11-20
Recruiting
Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer
NCT07563205Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer NSCLC, Non Small Cell Lung Carcinoma
GFPC Investigation
Observational
100
Aix-en-Provence, Bobigny, Bron, Caen, Créteil, Le Chesnay, Lille, Lyon
2025-11-19
Recruiting
Summit Therapeutics
Phase 3
600
Bordeaux, Lille, Lyon, Marseille, Montpellier, Nantes, Nice, Paris
2025-11-18
Recruiting
BIOCHROMADERM® PMCF STUDY
NCT07261904Reconstruction of the Nipple-areola Complex in Patients Undergoing Breast Reconstructive Surgery Following Mastectomy
Laboratoires BIOTIC Phocea
Observational
115
Lille, Marseille, Vandœuvre-lès-Nancy
2025-11-12
Recruiting
Novartis Pharmaceuticals
Phase 3
1,275
Limoges, Ajaccio, Amiens, Clermont-Ferrand, Grenoble, Lille, Montpellier, Nancy
2025-11-11
Recruiting
University Hospital, Lille
Not applicable
616
Bobigny, Levallois-Perret, Lille, Limoges, Nantes, Paris, Pierre-Bénite, Poitiers
2025-11-07
Recruiting
Nantes University Hospital
Phase 3
478
Chambray-lès-Tours, Lille, Lyon, Marseille, Metz, Montpellier, Nantes, Paris
2025-11-07
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
65
Nice, Nantes, Pierre-Bénite, Dijon, Lille, Marseille, Montpellier, Paris
2025-11-06
Recruiting
Bristol-Myers Squibb
Phase 2/3
500
Strasbourg, Toulouse, Lille, La Tronche, Saint-Herblain, Bron, Villejuif, Marseille
2025-11-05
Recruiting
Centre Leon Berard
Phase 1/2
70
Angers, Bordeaux, Bron, Lille, Lyon, Marseille, Paris, Toulouse
2025-11-04
Recruiting
Novartis Pharmaceuticals
Phase 2
30
Bordeaux, Bron, Le Kremlin-Bicêtre, Lille, Paris
2025-11-03
Not yet open
Universite du Littoral Cote d'Opale
Not applicable
102
Lille
2025-11-01
Recruiting
Resilience
Not applicable
594
Besançon, Grenoble, La Roche-sur-Yon, Lille, Lisieux, Toulouse
2025-10-31
Recruiting
French Cardiology Society
Observational
1,000
Lille, Paris
2025-10-30
Recruiting
Assistance Publique - Hôpitaux de Paris
Phase 3
348
Bordeaux, Bron, Garches, Le Kremlin-Bicêtre, Lille, Marseille, Nancy, Paris
2025-10-28
Recruiting
Daiichi Sankyo
Phase 3
686
Angers, Bordeaux, Boulogne-Billancourt, Bron, Créteil, Dijon, Lille, Lyon
2025-10-24
Recruiting
Eli Lilly and Company
Phase 3
1,630
Angers, Bayonne, Besançon, Bordeaux, Brest, Lille, Limoges, Lyon Cedex08
2025-10-22
Recruiting
Institut Claudius Regaud
Not applicable
130
Angers, Bordeaux, Caen, Lille, Lyon, Marseille, Montpellier, Paris
2025-10-21
Recruiting
Pharvaris Netherlands B.V.
Phase 3
48
Grenoble, Lille, Paris
2025-10-16
Recruiting
Eli Lilly and Company
Phase 3
4,500
Amiens, Angers, Besançon, Clichy, Dijon, La Roche-sur-Yon, Lille, Limoges
2025-10-15
Recruiting
Institut Claudius Regaud
Phase 4
210
Angers, Dijon, Lille, Marseille, Nîmes, Paris, Rennes, Strasbourg
2025-10-15
Recruiting
University Hospital, Clermont-Ferrand
Not applicable
42
Amiens, Clermont-Ferrand, Lille, Lyon, Marseille, Montpellier, Nice, Toulouse
2025-10-13
Recruiting
Sanofi
Phase 3
980
Lille, Nice, Vandœuvre-lès-Nancy
2025-10-08
Recruiting
Genentech, Inc.
Phase 1/2
285
Reims, Villejuif, Caen, Lille, Rennes
2025-10-07
Recruiting
Janssen Research & Development, LLC
Phase 2/3
1,092
Bayonne, Clermont-Ferrand, Créteil, Échirolles, Lille, Montfermeil, Montpellier, Nantes
2025-10-03
Recruiting
University Hospital, Lille
Observational
90
Lille
2025-10-03
Recruiting
University Hospital, Toulouse
Phase 4
200
Amiens, Bordeaux, Cahors, Dax, Le Mans, Lille, Limoges, Marseille
2025-10-02
Recruiting
Janssen Research & Development, LLC
Phase 3
882
Bayonne, Clermont-Ferrand, Créteil, Échirolles, Lille, Limoges, Montfermeil, Montpellier
2025-10-01
Recruiting
Sanofi
Phase 3
980
Amiens, Saint-Etienne, Besançon, Créteil, La Tronche, Lille, Marseille, Nantes
2025-10-01
Active, closed
Hospices Civils de Lyon
Phase 2
27
Angers, Bordeaux, Bron, Lille, Lyon, Marseille, Montpellier, Paris
2025-10-01
Recruiting
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
NCT05745714Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
DrugsRuxolitinib·Cytarabine·Venetoclax·Dexamethasone
Princess Maxima Center for Pediatric Oncology
Phase 1/2
26
Bordeaux, Lille, Lyon, Marseille, Nantes, Paris
2025-10-01
Not yet open
Hospices Civils de Lyon
Not applicable
516
Ivry-sur-Seine, Lille, Lyon, Nantes, Rennes, Saint-Victor-de-Cessieu, Strasbourg, Toulouse
2025-10-01
Recruiting
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
NCT05751044Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
DrugsDasatinib·Cytarabine·Venetoclax·Dexamethasone
Princess Maxima Center for Pediatric Oncology
Phase 1/2
26
Bordeaux, Lille, Lyon, Marseille, Nantes, Paris
2025-10-01
Recruiting
Pfizer
Phase 3
680
Brest, Toulouse, Rennes, Saint-Herblain, Lille, Villejuif, Bordeaux, Marseille
2025-09-29
Recruiting
Alfasigma S.p.A.
Phase 3
80
Bron, Dijon, Lille, Montpellier, Rennes, Tours
2025-09-29
Recruiting
Kura Oncology, Inc.
Phase 3
1,300
Clermont-Ferrand, Pierre-Bénite, Saint-Priest-en-Jarez, Mulhouse, Vandœuvre-lès-Nancy, Nantes, Pessac, Lille
2025-09-26
Recruiting
Sanofi
Phase 3
124
Clichy, Dijon, Lille, Lyon, Marseille, Pessac, Suresnes
2025-09-26
Recruiting
Study of the Determinants of Coronary Atherosclerosis in Familial Hypercholesterolemia (ATHERO-FH Study)
NCT06960902Familial Hypercholesterolemias, Atherosclerotic Cardiovascular Disease (ASCVD)
Nantes University Hospital
Not applicable
600
Dijon, Lille, Lyon, Marseille, Nantes, Paris, Rennes, Strasbourg
2025-09-25
Recruiting
University Hospital, Rouen
Phase 3
188
Amiens, Beauvais, Besançon, Bicêtre, Bordeaux, Clermont-Ferrand, Lille, Marseille
2025-09-25
Recruiting
Sanofi
Phase 4
218
La Tronche, Lille, Lyon, Marseille, Montpellier, Pessac, Reims
2025-09-22
Recruiting
The Lymphoma Academic Research Organisation
Phase 2
60
Bordeaux, Caen, Clermont-Ferrand, Lille, Marseille, Nancy, Paris, Pierre-Bénite
2025-09-22
Recruiting
Centre Hospitalier Universitaire de Nice
Phase 4
50
Nice, Créteil, Garches, Grenoble, Lille, Marseille, Nancy, Rouen
2025-09-19
Active, closed
Hoffmann-La Roche
Phase 3
1,101
Le Kremlin Bicétre Cedex, Lille, Marseille, Paris, Rennes, Toulouse, Tours, Vandœuvre-lès-Nancy
2025-09-17
Recruiting
Bioprojet
Phase 2
50
Amiens, Besançon, Bron, Clermont-Ferrand, Créteil, Lille, Marseille, Nancy
2025-09-17
Recruiting
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
NCT07091630Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
DrugEmpasiprubart
argenx
Phase 3
160
Lille, Paris, Créteil, Bourdeaux, Nice
2025-09-16
Active, closed
A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
414
Angers, Bordeaux, Lille, Paris, Rennes, Strasbourg, Toulouse
2025-09-13
Recruiting
French Cardiology Society
Not applicable
266
Besançon, Caen, Chambray-lès-Tours, Clermont-Ferrand, Grenoble, La Rochelle, Lille, Lomme
2025-09-10
Recruiting
Pfizer
Phase 3
140
Bron, Dijon, Lille, Nice, Toulouse
2025-09-10
Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
DrugsCasdatifan·Cabozantinib
Arcus Biosciences, Inc.
Phase 3
720
Angers, Brest, Caen, Clermont-Ferrand, Lille, Marseille, Montpellier, Paris
2025-09-08
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
125
Strasbourg, Lille
2025-09-04
Recruiting
University Hospital, Toulouse
Observational
200
Amiens, Lille, Lyon, Montpellier, Nantes, Nice, Rouen, Toulouse
2025-09-03
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Dijon, Epagny Metz-Tessy, La Tronche, Lille, Lyon, Nantes, Nice, Paris
2025-09-02
Recruiting
Janssen Research & Development, LLC
Phase 3
1,203
Bordeaux, Brest, Dijon, Lille, Lyon, Paris, Pierre-Bénite, Saint-Herblain
2025-09-02
Not yet open
Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France
NCT07038863HEPATITIS C (HCV), Hepatitis B Virus (HBV), Hepatitis D, Hepatocellular Carcinoma (HCC)
Hospices Civils de Lyon
Not applicable
2,000
Annecy, Bordeaux, Clermont-Ferrand, Créteil, Grenoble, Lille, Lyon, Rennes
2025-09-01
Not yet open
Hospices Civils de Lyon
Observational
268
Besançon, Bron, Clermont-Ferrand, Lille, Limoges, Nîmes, Paris, Saint-Etienne
2025-09-01
Not yet open
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2
162
Amiens, Besançon, Caen, La Roche-sur-Yon, Lille, Lyon, Paris, Pessac
2025-09
Not yet open
Assistance Publique - Hôpitaux de Paris
Phase 2/3
526
Clermont-Ferrand, Le Kremlin-Bicêtre, Lille, Lyon, Marseille, Paris, Rouen, Toulouse
2025-09
Not yet open
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2
160
Bayonne, Bordeaux, Brest, Carcassonne, Clermont-Ferrand, Dijon, Lille, Marseille
2025-09
Not yet open
Assistance Publique - Hôpitaux de Paris
Not applicable
346
Lille, Marseille, Paris, Rouen, Suresnes, Villejuif
2025-09
Recruiting
BeOne Medicines
Phase 3
351
Avignon, Brest, Lille
2025-08-27
Recruiting
Mirum Pharmaceuticals, Inc.
Phase 3
172
Clermont-Ferrand, Clichy, Créteil, La Tronche, Le Chesnay, Lille, Limoges, Lyon
2025-08-27
Recruiting
The Lymphoma Academic Research Organisation
Phase 1/2
49
Caen, Clermont-Ferrand, Créteil, Dijon, La Tronche, Le Mans, Lille, Marseille
2025-08-20
Recruiting
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
NCT07005154Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
DrugsPRL-02·Abiraterone acetate·Prednisolone·Prednisone
Astellas Pharma Global Development, Inc.
Phase 2
218
Bordeaux, Le Mans, Lille, Paris, Strasbourg
2025-08-19
Recruiting
University Hospital, Antwerp
Not applicable
50
Lille
2025-08-13
Recruiting
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase 1
15
Avignon, Besançon, Brest, Lille, Lyon, Pessac, Poitiers, Reims
2025-08-08
Active, closed
AstraZeneca
Phase 3
212
Amiens, Bois-Guillaume, Bordeaux, Lille, Paris
2025-08-07
Recruiting
AbbVie
Phase 1
135
Nice, Marseille, Lille, Tours, Toulouse
2025-08-07
Recruiting
ACADIA Pharmaceuticals Inc.
Phase 2
180
Toulouse, Lille, Paris, Villeurbanne, Bron, Strasbourg, Tours, Vandœuvre-lès-Nancy
2025-08-06
Recruiting
Sanofi
Phase 3
723
Bron, La Tronche, Lille, Paris, Pau, Strasbourg
2025-08-06
Recruiting
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3
227
Angers, Bordeaux, Caen, Créteil, Grenoble, Lille, Lyon, Montpellier
2025-08-05
Recruiting
University Hospital, Rouen
Not applicable
6
Amiens, Caen, Lille, Rouen
2025-08-01
Recruiting
AstraZeneca
Phase 3
800
Avignon, Besançon, Bordeaux, Chambray-lès-Tours, Cholet, Créteil, Grenoble, Lille
2025-08-01
Active, closed
Pfizer
Phase 3
208
Bron, Dijon, Lille, Nice, Toulouse
2025-07-31
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
298
Brest, Lille, Paris
2025-07-30
Recruiting
CSL Behring
Phase 3
20
Lille, Marseille
2025-07-28
Recruiting
Celgene
Phase 3
400
Pessac, Saint-Cloud, Montpellier, Nantes, Lille, Pierre-Bénite, Paris, Toulouse
2025-07-28
Recruiting
Hospices Civils de Lyon
Not applicable
482
Bordeaux, Dijon, Grenoble, Jossigny, Lille, Lyon, Marseille, Nantes
2025-07-25
Recruiting
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
DrugsZanzalintinib·Everolimus
Exelixis
Phase 2/3
440
Caen, Clichy, Lille, Lyon, Marseille, Montpellier, Nantes, Rennes
2025-07-21
Recruiting
Bristol-Myers Squibb
Phase 3
586
Marseille, Tours, Toulouse, Lille, Rennes, Saint-Herblain, Nancy, Bron
2025-07-21
Active, closed
Compugen Ltd
Phase 1/2
60
Besançon, Toulouse, Lille, Marseille, Pierre-Bénite, Rennes, Saint-Herblain, Villejuif
2025-07-21
Active, closed
Lyv Healthcare
Not applicable
400
Aix-en-Provence, Caen, Rennes, Bordeaux, Le Chesnay, Le Mans, Lille, Paris
2025-07-21
Recruiting
Predictive Value of the Optic Nerve Involvement in Clinically Isolated Syndrome
NCT06455332Clinically Isolated Syndrome, Multiple Sclerosis
University Hospital, Lille
Not applicable
200
Lille
2025-07-17
Recruiting
Bristol-Myers Squibb
Phase 3
426
Toulouse, Villeurbanne, Lille, Limoges, Montpellier, Paris, Strasbourg
2025-07-16
Recruiting
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
NCT06570798Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
DrugsUplizna·Inebilizumab·Blinatumomab
Amgen
Phase 2
220
Le Kremlin-Bicêtre, Lille, Lyon, Lyon Cédex 3, Marseille, Paris, Strasbourg, Toulouse
2025-07-16
Recruiting
Clinical and Radiological Outcomes of the ROMAX Hip Resurfacing System
NCT06775704Arthritis (Hip), Hip Dysplasia, Congenital
Medacta International SA
Observational
150
Lille
2025-07-14
Recruiting
Pfizer
Phase 3
300
Lille, Dijon, Paris
2025-07-14
Recruiting
4TEEN4 Pharmaceuticals GmbH
Phase 1/2
90
Bobigny, Dijon, Lille, Limoges, Nancy, Paris
2025-07-13
Recruiting
University Hospital, Lille
Phase 1
5
Lille
2025-07-10
Active, closed
Sanofi
Phase 2
105
Lille, Montpellier, Nice, Pierre-Bénite, Saint-Priest-en-Jarez, Toulouse
2025-07-07
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
360
Bordeaux, Lille, Saint-Herblain, Bayonne, Pierre-Bénite
2025-07-03
Recruiting
University Hospital, Angers
Observational
40
Angers, Lille
2025-07-01
Not yet open
University Hospital, Rouen
Observational
100
Amiens, Lille, Rouen
2025-07-01
Not yet open
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2
206
Besançon, La Tronche, Lille, Paris, Poitiers, Reims, Saint-Cloud, Saint-Etienne
2025-07
Recruiting
Intergroupe Francophone de Cancerologie Thoracique
Phase 2
38
Besançon, Brest, Caen, Clermont-Ferrand, Créteil, Grenoble, Le Mans, Lille
2025-06-30
Active, closed
Mundipharma Research Limited
Phase 2
60
Amiens, Lille, Montpellier, Pessac
2025-06-30
Recruiting
Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube Carcinoma
NCT06969833Cancer of the Ovary, Cancer of the Fallopian Tube, Peritoneal Cancer
Centre Oscar Lambret
Not applicable
371
Lille
2025-06-27
Recruiting
Hoffmann-La Roche
Phase 3
75
Lille, Paris
2025-06-27
Recruiting
Assistance Publique - Hôpitaux de Paris
Observational
14
Bordeaux, Lille, Marseille, Paris, Toulouse
2025-06-26
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
5,056
Amiens, Béziers, Bron, Dijon, Lille, Montpellier, Nantes, Nice
2025-06-25
Active, closed
DBV Technologies
Phase 3
480
Angers, Bron, Lille, Montpellier, Vandœuvre-lès-Nancy
2025-06-24
Recruiting
Assistance Publique - Hôpitaux de Paris
Phase 3
86
Besançon, Bordeaux, Brest, Bron, Le Kremlin-Bicêtre, Lille, Montpellier, Strasbourg
2025-06-23
Recruiting
Novartis Pharmaceuticals
Phase 3
400
Bordeaux, Clermont-Ferrand, Lille, Marseille, Nice, Nîmes, Paris, Poitiers
2025-06-23
Active, closed
Novartis Pharmaceuticals
Phase 1/2
27
Bordeaux, Brest, Le Kremlin-Bicêtre, Lille
2025-06-20
Active, closed
ANRS, Emerging Infectious Diseases
Phase 1/2
48
Caen, Clermont-Ferrand, Créteil, Lille, Nantes, Paris
2025-06-18
Recruiting
Efficacy and Safety of Vaginal Radiofrequency for Vulvovaginal Atrophy in Breast Cancer Patients
NCT06900374Vaginal Dryness, Breast Cancer, Vulvovaginal Atrophy
Centre Oscar Lambret
Not applicable
75
Lille
2025-06-12
Recruiting
Grupo Espanol de Tumores Neuroendocrinos
Phase 3
166
Caen, Dijon, Lille, Lyon, Marseille, Clichy, Paris, Villejuif
2025-06-12
Recruiting
Boehringer Ingelheim
Phase 3
1,755
Amiens, Créteil, Lille, Lyon, Montpellier, Nice, Paris, Pessac
2025-06-09
Recruiting
University Hospital, Toulouse
Phase 4
308
Toulouse, Amiens, Bordeaux, Brest, Clermont-Ferrand, Le Mans, Lille, Limoges
2025-06-06
Active, closed
Incyte Corporation
Phase 3
9
Amiens, Caen, Lille, Marseille, Nantes, Nice, Paris, Pessac
2025-06-04
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Angers, Clermont-Ferrand, Lille, Marseille, Montpellier, Nice, Paris, Pierre-Bénite
2025-06-04
Recruiting
AstraZeneca
Phase 3
15,100
Bordeaux, Brest, Bron, Corbeil-Essonnes, Dijon, La Tronche, Lille, Limoges
2025-06-04
Not yet open
Pilot Study of PEnile TRAnsplantation - Vascularized Composite Allografts
NCT06781606Adults with Traumatic Penile Severe Defects, Congenital Penile Defects, Micropenis
Hospices Civils de Lyon
Not applicable
3
Bordeaux, Lille, Lyon, Marseille, Montpellier, Pierre-Bénite, Suresnes, Toulouse
2025-06-01
Recruiting
Swedish Orphan Biovitrum
Phase 2
156
Lille, Paris, Pierre-Bénite, Poitiers, Toulouse
2025-05-28
Recruiting
AbbVie
Phase 2
110
Caen, Plérin, Vandœuvre-lès-Nancy, Lille, Nice, Pierre-Bénite, La Roche-sur-Yon, Paris
2025-05-28
Recruiting
EARLY DETECTION OF DEAFNESS IN A MEMORY CENTER
NCT06088953Cognitive Disorder, Deafness
University Hospital, Lille
Not applicable
200
Lille
2025-05-27
Recruiting
EURO-STIM Registry
NCT06971796Obstructive Sleep Apnea, Obstructive Sleep Apnea (OSA)
Inspire Medical Systems, Inc.
Observational
1,000
Angers, La Tronche, Lille, Marseille, Montpellier, Saint-Priest-en-Jarez
2025-05-26
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
500
Bordeaux, Brest, Caen, Carassonne, Dijon, Lille, Lyon, Montpellier
2025-05-22
Recruiting
Eikon Therapeutics
Phase 2/3
740
Pierre-Bénite, Boulogne, La Tronche, Lille, Marseille, Nice, Paris, Saint-Herblain
2025-05-22
Active, closed
UroMems SAS
Not applicable
140
Lille, Marseille, Nantes, Paris, Pierre-Bénite, Rennes, Rouen, Suresnes
2025-05-19
Recruiting
Novartis Pharmaceuticals
Phase 2
224
Brest, Lille, Lorient, Paris, Pierre-Bénite, Reims, Rouen
2025-05-16
Recruiting
University Hospital, Tours
Not applicable
140
Angers, Lille, Montpellier, Nantes, Orléans, Strasbourg, Tours
2025-05-16
Recruiting
Corxel Pharmaceuticals
Phase 2/3
740
Lille, Nancy, Paris, Rouen, Toulouse, Tours
2025-05-15
Recruiting
Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
NCT06960577Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine
DrugsVinblastine·Methotrexate·Doxorubicin·Durvalumab
AstraZeneca
Phase 2
150
Angers, Bordeaux, Chambray-lès-Tours, Dijon, Lille, Lyon, Marseille, Montpellier
2025-05-15
Recruiting
Surgical vs Transcatheter Aortic Valve Replacement in YOUNG Patients
NCT06861361Symptomatic Severe Aortic Stenosis
Ceric Sàrl
Not applicable
1,180
Lille, Lyon, Massy, Rouen, Toulouse
2025-05-15
Recruiting
University Hospital, Lille
Observational
97
Lille
2025-05-14
Active, closed
Boehringer Ingelheim
Phase 1
91
Lille, Lyon, Marseille, Villejuif
2025-05-14
Recruiting
Hoffmann-La Roche
Phase 3
425
Pierre-Bénite, Chambray-lès-Tours, Clermont-Ferrand, Créteil, La Roche-sur-Yon, Lille, Limoges, Montpellier
2025-05-12
Recruiting
Safety of HRX215 in Patients After Minor and Major Liver Resection
NCT06638502Liver Resection, Colorectal Carcinoma Liver Metastases
HepaRegeniX GmbH
Phase 1/2
80
Lille, Villejuif
2025-05-06
Recruiting
AstraZeneca
Phase 3
1,220
Clichy, Lille, Lyon, Montpellier, Nantes, Nice, Pessac, Rennes
2025-05-06
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
DrugsCetuximab·Docetaxel
Revolution Medicines, Inc.
Phase 3
590
Strasbourg, Marseille, Montpellier, Rennes, La Tronche, Saint-Herblain, Léon, Lille
2025-05-06
Not yet open
Hospices Civils de Lyon
Not applicable
80
Bordeaux, Lille, Saint-Genis-Laval
2025-05-01
Active, closed
Novartis Pharmaceuticals
Phase 3
246
Béziers, Cholet, Grenoble, Lille, Montpellier, Paris, Pessac, Poitiers
2025-04-30
Recruiting
Centre Francois Baclesse
Phase 3
116
Caen, Lille, Rouen
2025-04-30
Active, closed
Hoffmann-La Roche
Observational
44
Lille, Paris
2025-04-29
Recruiting
Fondation Ophtalmologique Adolphe de Rothschild
Phase 3
128
Bordeaux, Garches, Lille, Lyon, Nice, Paris, Strasbourg, Toulouse
2025-04-29
Recruiting
AbbVie
Phase 2
390
Lille, Poitiers, Nantes, Paris
2025-04-24
Active, closed
Novartis Pharmaceuticals
Phase 1/2
15
Bordeaux, Brest, Lille
2025-04-22
Recruiting
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
NCT06512883Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES)
DrugsFasenra·Benralizumab
AstraZeneca
Phase 3
14
Lille, Montpellier
2025-04-17
Recruiting
ENDOmetriosis Robotic Assisted Surgery
NCT06445179Endometriosis
GCS Ramsay Santé pour l'Enseignement et la Recherche
Not applicable
224
Aix-en-Provence, Lille
2025-04-16
Recruiting
University Hospital, Limoges
Phase 4
162
Besançon, Clichy, Dijon, Grenoble, Lille, Limoges, Lyon, Marseille
2025-04-15
Active, closed
University Hospital, Tours
Observational
80
Brest, Clermont-Ferrand, Lille, Limoges, Lyon, Nice, Tours
2025-04-11
Recruiting
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
NCT06906341Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
DrugsNab-paclitaxel /m^2·Relacorilant·Bevacizumab
Corcept Therapeutics
Phase 2
270
Lille, Nancy, Nice, Pierre-Bénite, Plérin, Toulouse
2025-04-11
Recruiting
Hoffmann-La Roche
Phase 3
450
Angers, Lille, Montpellier, Paris, Plérin, Poitiers, Rennes, Rouen
2025-04-09
Recruiting
Merck Sharp & Dohme LLC
Phase 3
770
Lille, Bordeaux, Pierre-Bénite, Caen, Plérin, Toulouse, Chambray-lès-Tours, Paris
2025-04-09
Recruiting
Impaired Type I IFN Immunity Due to Autoantibodies or a Genetic Defect: a Prospective National Cohort
NCT06762002Immunology, Allergy, Genetic Diseases, Infectious Diseases
Institut National de la Santé Et de la Recherche Médicale, France
Observational
500
Lille, Lyon, Montpellier, Paris, Tours
2025-04-09
Recruiting
Institut Claudius Regaud
Not applicable
150
Angers, Bordeaux, Caen, Lille, Lyon, Marseille, Montpellier, Nantes
2025-04-07
Recruiting
Lille University
Observational
350
Lille
2025-04-02
Recruiting
Resilience
Phase 3
1,458
Aix-en-Provence, Aurillac, Bayonne, Caen, Clermont-Ferrand, La Tronche, Lille, Lyon
2025-04-01
Recruiting
Madeleine Bezault
Phase 2
80
Clermont-Ferrand, Créteil, Le Kremlin-Bicêtre, Lille, Lyon, Marseille, Montpellier, Nancy
2025-03-31
Recruiting
Daiichi Sankyo
Phase 3
510
Avignon, Brest, Dijon, Lille, Lyon, Marseille, Montpellier, Nantes
2025-03-27
Recruiting
Rennes University Hospital
Phase 4
400
Chambray-lès-Tours, Clichy, Lille, Lyon, Montpellier, Pessac, Rennes, Villejuif
2025-03-26
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
270
Marseille, Rennes, Lille, Villejuif
2025-03-25
Recruiting
University Hospital, Lille
Observational
432
Lille
2025-03-23
Recruiting
Medtronic MiniMed, Inc.
Not applicable
40
Bordeaux, Corbeil-Essonnes, Lille, Montpellier, Nancy, Toulouse, Dijon, Marseille
2025-03-21
Recruiting
Metabolic Fluid Responsiveness in Children
NCT07255469Circulatory Failure / Shock State, Fluid Therapy
University Hospital, Bordeaux
Observational
110
Bron, Lille, Marseille, Nantes, Paris, Pessac, Toulouse, Saint-Denis
2025-03-21
Recruiting
Evaluation of Urinary Dysfunction in CANVAS Patients
NCT06817707Cerebellar Ataxia, Neuropathy, Vestibular Areflexia
Centre Hospitalier Universitaire de Nice
Not applicable
40
Nice, Montpellier, Lille
2025-03-21
Active, closed
Astria Therapeutics, Inc.
Phase 3
157
La Tronche, Lille, Marseille, Nice, Paris
2025-03-20
Recruiting
Daiichi Sankyo
Phase 3
582
Bordeaux, Dijon, Lille, Lyon, Montpellier, Nantes, Paris, Rennes
2025-03-19
Recruiting
University Hospital, Lille
Observational
1,000
Lille
2025-03-19
Recruiting
Study of Sleep Disorders in Prodromal and Definite Parkinsons Disease
NCT06582121Parkinson Disease, REM Sleep Behavior Disorder (iRBD)
Assistance Publique - Hôpitaux de Paris
Not applicable
457
Clermont-Ferrand, Lille, Lyon, Nantes, Nîmes, Paris
2025-03-18
Recruiting
Lille University
Not applicable
54
Lille
2025-03-15
Recruiting
Insel Gruppe AG, University Hospital Bern
Phase 4
906
Bordeaux, Grenoble, Lille, Lyon, Montpellier, Nancy, Paris, Perpignan
2025-03-14
Recruiting
Lille University
Observational
20
Lille
2025-03-13
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
440
Lille, Nantes, Pierre-Bénite, Créteil, Paris
2025-03-12
Recruiting
Institut Pasteur de Lille
Not applicable
35
Lille
2025-03-10
Active, closed
Swedish Orphan Biovitrum
Phase 3
89
Brest, Bron, Lille
2025-03-06
Recruiting
Irritable Bowel Syndrome Regional Cohort
NCT06900491Irritable Bowel Syndrome
University Hospital, Rouen
Observational
600
Amiens, Caen, Lille, Rouen
2025-03-04
Not yet open
Arginin-stimulated Copeptin in Polyuria-polydipsia Syndrome in Children
NCT06604975Primary Polydipsia, Central Diabetes Insipidus, Nephrogenic Diabetes Insipidus
Assistance Publique Hopitaux De Marseille
Not applicable
155
Angers, Bordeaux, Lille, Lyon, Marseille, Montpellier, Nantes, Nice
2025-03
Recruiting
Centre Hospitalier Universitaire de Besancon
Not applicable
226
Besançon, Bordeaux, Grenoble, Lille, Lyon, Marseille, Nancy, Nantes
2025-03
Recruiting
Summit Therapeutics
Phase 3
780
Nantes, Avignon, Brest, Créteil, Lille, Lyon, Marseille, Paris
2025-02-27
Recruiting
Daiichi Sankyo
Phase 3
726
Avignon, Brest, Dijon, Grenoble, Lille, Lyon, Montpellier, Nantes
2025-02-27
Recruiting
Biocollection of Rare Pediatric-onset of Autoimmune and Autoinflammatory Diseases
NCT06435468Systemic Lupus, Autoimmune Diseases, Autoinflammatory Disease, Genetic Disease
Hospices Civils de Lyon
Not applicable
400
Bron, Lille, Nice, Paris, Saint-Etienne, Grenoble, Rouen, Strasbourg
2025-02-26
Recruiting
Assistance Publique - Hôpitaux de Paris
Phase 3
300
Boulogne-Billancourt, Lille, Marseille, Nantes, Paris
2025-02-26
Recruiting
Ferrer Internacional S.A.
Observational
60
Bron, Grenoble, Lille, Toulouse
2025-02-25
Recruiting
Bristol-Myers Squibb
Phase 3
530
Montpellier, La Tronche, Lille, Gleizé, Pierre-Bénite, Créteil, Villejuif, Marseille
2025-02-25
Recruiting
The Lymphoma Academic Research Organisation
Phase 2
100
Créteil, Dijon, Lille, Marseille, Montpellier, Nantes, Pierre-Bénite, Reims
2025-02-21
Recruiting
Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma
NCT06706401Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer, Primary Head and Neck Tumor
DrugsVesanoid·ATRA·Cetuximab·Cisplatin
Centre Leon Berard
Phase 3
460
Lyon, Vandœuvre-lès-Nancy, Villejuif, Angers, Lille, Nice, Paris, Reims
2025-02-20
Recruiting
Prospective Cohort Study of Protected Children
NCT06805682Mental Health Conditions, Physical Health Status, Child Development
Assistance Publique - Hôpitaux de Paris
Observational
220
Évreux, Lille, Metz, Rouen, Saint-Brieuc, Saint-Genest-Lerpt, Toulon
2025-02-18
Recruiting
Novartis Pharmaceuticals
Phase 2
20
Bordeaux, Lille, Lyon, Nantes, Paris, Vandœuvre-lès-Nancy
2025-02-18
Recruiting
Improvement of Symptoms After Removal of the Essure® Contraceptive Implant
NCT06355713Implant Complication, Contraceptive Device; Complications
DrugBlood sample
Hospices Civils de Lyon
Not applicable
444
Angers, Bron, Le Kremlin-Bicêtre, Lille, Marseille, Reims, Rouen, Strasbourg
2025-02-17
Recruiting
Bayer
Phase 2
111
Pierre-Bénite, Brest, Lille, Bordeaux, Montpellier, Villejuif
2025-02-13
Recruiting
French Validation of Schizophrenia Proneness Instrument- Child Youth
NCT06649552Clinical High Risk for Psychosis (CHR)
Centre Psychothérapique de Nancy
Not applicable
52
Lille, Nancy, Saint-Egrève
2025-02-13
By invitation
Longboard Pharmaceuticals
Phase 3
324
Strasbourg, Bron, Lille, Marseille, Paris, Toulouse
2025-02-12
Recruiting
Non-inferiority of Continuing Oral Intake Versus Fasting in Patients With Acute Respiratory Failure
NCT06510972Respiratory Insufficiency, Fasting, Dysphagia, Swallowing Disorder
University Hospital, Tours
Not applicable
754
Blois, Bourges, Colombes, Dreux, La Roche-sur-Yon, Le Mans, Lille, Morlaix
2025-02-05
Recruiting
Maze Therapeutics
Phase 2
74
Créteil, Lille, Lyon, Paris, Saint-Ouen
2025-02-05
Recruiting
LEOPARD Training and Validation Data Collection Study
NCT06675604Decompensated Liver Cirrhosis, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Hepato-cellular Carcinoma
Assistance Publique - Hôpitaux de Paris
Observational
4,500
Besançon, Chambray-lès-Tours, Clichy, Créteil, Dijon, Lille, Lyon, Marseille
2025-02-04
Recruiting
Topadur Pharma AG
Phase 2
15
Bordeaux, La Tronche, Lille, Paris
2025-02-04
Recruiting
Airway Therapeutics, Inc.
Phase 2/3
366
Lille, Nancy, Nice, Paris, Poissy
2025-02-03
Not yet open
Institut Cancerologie de l'Ouest
Phase 2
114
Caen, Dijon, Lille, Limoges, Marseille, Montpellier, Paris, Pierre-Bénite
2025-02
Not yet open
University Hospital, Strasbourg, France
Observational
100
Besançon, Bron, Clermont-Ferrand, Créteil, Grenoble, Lille, Limoges, Marseille
2025-02
Recruiting
AbbVie
Observational
1,200
Nice, Caluire-et-Cuire, Clermont-Ferrand, Échirolles, Besançon, Arras, Lille, Montpellier
2025-01-31
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
Bordeaux, Dijon, Lille, Paris, Saint-Herblain, Suresnes, Toulouse, Villejuif
2025-01-29
Recruiting
Social & Affective Cognition in Alzheimer's Disease & Associated Disorders
NCT06338397Alzheimer's Disease, Frontotemporal Degeneration (Semantic & Behavioral Variants)
University Hospital, Lille
Not applicable
120
Lille
2025-01-28
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsFicerafusp alfa·Keytruda·Pembrolizumab
Bicara Therapeutics
Phase 2/3
650
Amiens, Bordeaux, Lille, Lyon, Paris, Rennes, Saint-Grégoire, Strasbourg
2025-01-28
Active, closed
Intellia Therapeutics
Phase 3
80
Grenoble, Lille, Marseille
2025-01-15
Recruiting
GCS-CCOMS
Not applicable
6,500
Armentières, Bailleul, Étampes, Laxou, Lille, Nanterre, Paris, Rouffach
2025-01-15
Recruiting
Immatics US, Inc.
Phase 3
360
Lille, Paris, Villejuif
2025-01-14
Recruiting
Centre Leon Berard
Not applicable
236
Angers, Besançon, Bordeaux, Caen, Lille, Lyon, Nancy, Nice
2025-01-14
Recruiting
Centre Oscar Lambret
Phase 2
85
Lille
2025-01-13
Recruiting
Bronchiolitis Clearance Airways With Seaserum
NCT06177197Bronchiolitis Acute
University Hospital, Brest
Not applicable
458
Brest, Le Mans, Lille, Marseille, Morlaix, Nantes, Rennes, Tours
2025-01-10
Active, closed
Daiichi Sankyo
Phase 2
335
Caen, Dijon, Lille, Lyon, Paris, Plérin, Saint-Herblain, Toulouse
2025-01-06
Active, closed
Pfizer
Phase 3
1,035
Bayonne, Bordeaux, Lille, Saint-Cloud, Rennes, Montpellier, Saint-Herblain, Angers
2025-01-06
Recruiting
Takeda
Phase 3
396
Amiens, Lille, Marseille, Nantes, Pessac, Saint-Etienne, Toulouse, Vandœuvre-lès-Nancy
2025-01-02
Recruiting
Fondation Hôpital Saint-Joseph
Observational
2,000
Bordeaux, Le Plessis-Robinson, Lille, Toulouse
2025-01-01
Not yet open
University Hospital, Strasbourg, France
Phase 3
200
Bordeaux, Caen, Clermont-Ferrand, Créteil, Dijon, Gonesse, La Tronche, Lille
2025-01
By invitation
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
NCT06788509Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes
DrugsJNJ-75348780·JNJ-87801493·JNJ-80948543·Ibrutinib
Janssen Research & Development, LLC
Phase 1
120
Lille, Nantes, Villejuif
2024-12-30
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
32
Lille, Créteil, Villejuif
2024-12-20
Recruiting
Hospices Civils de Lyon
Observational
240
Clermont-Ferrand, Lille, Lyon, Nantes
2024-12-19
Active, closed
argenx
Phase 3
154
Bordeaux, Brest, Bron, Le Kremlin-Bicêtre, Lille, Limoges, Marseille, Nice
2024-12-18
Recruiting
Assistance Publique Hopitaux De Marseille
Not applicable
60
Bordeaux, Bron, Lille, Marseille, Paris, Rennes, Toulouse
2024-12-18
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
21
Brest, Lille, Lyon, Marseille, Paris, Rennes
2024-12-17
Recruiting
A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
NCT06747585Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma
Alentis Therapeutics AG
Phase 1/2
235
Bordeaux, Dijon, Lille, Marseille, Toulouse, Villejuif
2024-12-16
Recruiting
Central Hospital, Nancy, France
Phase 3
164
Ars-Laquenexy, Besançon, Dijon, Lille, Reims, Strasbourg, Vandœuvre-lès-Nancy
2024-12-16
Active, closed
Arcus Biosciences, Inc.
Phase 3
610
Dijon, Lille, Lyon, Poitiers, Villejuif
2024-12-13
Active, closed
Amgen
Phase 3
707
Bordeaux, Clermont-Ferrand, La Tronche, Le Mans, Lille, Lyon, Marseille, Nice
2024-12-09
Recruiting
Ryvu Therapeutics SA
Phase 2
178
Le Mans, Lille, Limoges, Lyon, Montpellier, Paris, Pessac
2024-12-05
Active, closed
Janssen Research & Development, LLC
Phase 3
655
Brest, Dijon, Le Kremlin-Bicêtre, Lille, Montpellier, Saint-Priest-en-Jarez, Strasbourg, Talence
2024-12-04
Active, closed
H. Lundbeck A/S
Phase 3
401
Rennes, Lille, Bordeaux, Montpellier, Toulouse, Marseille, Paris
2024-12-03
Active, closed
Pharvaris Netherlands B.V.
Phase 3
81
Grenoble, Lille
2024-12-01
Not yet open
University Hospital, Clermont-Ferrand
Observational
97
Clermont-Ferrand, Lille
2024-12
Recruiting
National Registry of Cardioneuroablation in Recurrent Reflex Syncope
NCT06159764Syncope, Vasovagal, Bradycardia, Heart Arrest
University Hospital, Bordeaux
Observational
50
Bron, Clermont-Ferrand, Lille, Marseille, Montpellier, Paris, Pessac, Rennes
2024-11-27
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,380
Nice, Neuilly-sur-Seine, Vandœuvre-lès-Nancy, Lille
2024-11-25
Recruiting
Washington University School of Medicine
Phase 2/3
280
Toulouse, Lille, Paris, Bron, Rouen
2024-11-22
Recruiting
Washington University School of Medicine
Phase 2/3
280
Toulouse, Lille, Paris, Bron, Rouen
2024-11-22
Recruiting
ADDICTOlogical Intervention in LIVEr Transplantation Recipients
NCT06472973Alcohol Associated Liver Disease, Liver Transplantation
University Hospital, Montpellier
Not applicable
720
Besançon, Bordeaux, Clermont-Ferrand, Dijon, Lille, Lyon, Marseille, Montpellier
2024-11-21
Recruiting
Biosency
Not applicable
380
Brest, Vannes, Le Coudray, Verdun, Lille, Montpellier, Toulouse, Marseille
2024-11-20
Active, closed
Daiichi Sankyo
Phase 3
700
Angers, Caen, La Tronche, Le Chesnay, Lille, Lyon, Marseille, Nantes
2024-11-19
Recruiting
Boehringer Ingelheim
Phase 3
1,590
Amiens, Angers, Clichy, Créteil, Dijon, Le Chesnay, Lille, Lyon
2024-11-12
Recruiting
Janssen Research & Development, LLC
Phase 3
39
Lille, Paris
2024-11-11
Active, closed
Longboard Pharmaceuticals
Phase 3
367
Lille, Toulouse, Bron, Marseille, Paris, Strasbourg, Villejuif
2024-11-11
Active, closed
argenx
Phase 2
87
Lille, Bordeaux, Marseille, Montpellier, Paris
2024-11-11
Recruiting
Anti-GD2 ADC M3554 in Advanced Solid Tumors
NCT06641908Advanced Solid Tumor
EMD Serono Research & Development Institute, Inc.
Phase 1
65
Bordeaux, Lille, Lyon, Nice
2024-11-08
Recruiting
Takeda
Phase 3
24
Lille, Lyon
2024-11-06
Recruiting
Imagine Institute
Observational
13,000
Amiens, Angers, Besançon, Caen, Clermont-Ferrand, Grenoble, Lille, Limoges
2024-11-01
Recruiting
Centre Hospitalier Universitaire de Saint Etienne
Phase 4
220
Le Kremlin-Bicêtre, Amiens, Lille, Limoges, Marseille, Montpellier, Nice, Paris
2024-10-31
Recruiting
Imagine Institute
Observational
400
Amiens, Angers, Besançon, Bordeaux, Brest, Clermont-Ferrand, Grenoble, Lille
2024-10-31
Recruiting
ESTEVE Pharmaceuticals SAS
Observational
85
Aubagne, Bron, Caen, La Roche-sur-Yon, Laon, Lille, Lorient, Lyon
2024-10-30
Recruiting
Sanofi
Phase 1
87
Lille, Nantes
2024-10-30
Recruiting
Regeneron Pharmaceuticals
Phase 3
975
Nice, Marseille, Poitiers, Toulouse, Créteil, Dijon, Lille, Lyon
2024-10-30
Recruiting
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
NCT06663332Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
DrugGuselkumab
Janssen Research & Development, LLC
Phase 3
196
Lille
2024-10-29
Active, closed
Novartis Pharmaceuticals
Phase 2
96
Bordeaux, Dijon, Lille, Lyon, Montpellier, Paris, Rennes, Strasbourg
2024-10-29
Active, closed
Eli Lilly and Company
Phase 2
45
Bordeaux, Lille, Lyon, Marseille, Paris, Villejuif
2024-10-25
Active, closed
Pfizer
Phase 3
600
Nice, Lyon Cedex08, Strasbourg, Brest, Nîmes, Toulouse, Lille, Suresnes
2024-10-21
Recruiting
Merck Sharp & Dohme LLC
Phase 3
680
Caen, Tours, Besançon, Saint-Herblain, Lille, Lyon, Paris, Villejuif
2024-10-21
Recruiting
Janssen Research & Development, LLC
Phase 3
1,000
Avignon, Lille, Lyon, Montpellier, Nantes, Paris, Pessac, Poitiers
2024-10-18
Recruiting
Perioperative Hemostasis Management in Liver Transplantation
NCT06257407Liver Transplant; Complications
Société Française d'Anesthésie et de Réanimation
Observational
1,200
Besançon, Clermont, Clichy, Grenoble, Lille, Lyon, Marseille, Montpellier
2024-10-17
Active, closed
Novartis Pharmaceuticals
Phase 2
251
Bron, Lille, Nice, Paris, Tours
2024-10-17
Recruiting
Boehringer Ingelheim
Phase 3
1,800
Amiens, Angers, Clichy, Créteil, Dijon, Le Chesnay, Lille, Lyon
2024-10-14
Active, closed
SynOx Therapeutics Limited
Phase 3
128
Bordeaux, Saint-Herblain, Paris, Lyon, Lille, Toulouse
2024-10-09
Active, closed
Novartis Pharmaceuticals
Phase 2
201
Dijon, Le Mans, Lille, Montpellier, Paris, Rennes, Strasbourg, Toulouse
2024-10-09
Recruiting
Bristol-Myers Squibb
Phase 3
1,000
Dijon, Brest, Toulouse, Montpellier, Rennes, Vandœuvre-lès-Nancy, Lille, Le Mans
2024-10-07
Recruiting
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
DrugEfruxifermin
Akero Therapeutics, Inc
Phase 3
2,150
Strasbourg, Pessac, Limoges, Lille, Clichy, Vandœuvre-lès-Nancy, Angers, Toulouse
2024-10-04
Active, closed
AstraZeneca
Phase 3
768
Bordeaux, Caen, Lille, Montpellier, Nantes, Paris, Pessac, Toulon Armees
2024-10-04
Not yet open
Lille Catholic University
Not applicable
104
Amiens, Caen, Lille, Lomme, Rouen
2024-10
Recruiting
Dexamethasone and Pregnancy: Maternal Effects
NCT06259994Dexamethasone During Pregnancy
Assistance Publique - Hôpitaux de Paris
Observational
35
Bordeaux, Bron, Grenoble, Le Kremlin-Bicêtre, Lille, Nantes, Paris, Toulouse
2024-09-30
Recruiting
GlaxoSmithKline
Phase 2
393
Angers, Bobigny, Créteil, Lille, Montpellier, Rouen
2024-09-27
Active, closed
Merus B.V.
Phase 3
699
Bordeaux, Le Mans, Lille, Lyon, Marseille, Montpellier, Nice, Paris
2024-09-25
Active, closed
Longboard Pharmaceuticals
Phase 3
108
Bron, Lille, Toulouse, Marseille, Paris, Strasbourg, Villejuif
2024-09-25
Recruiting
Rennes University Hospital
Not applicable
1,680
Lille, Limoges, Paris, Pierre-Bénite, Plérin, Rennes, Rouen, Saint-Etienne
2024-09-23
Active, closed
Hoffmann-La Roche
Phase 3
338
Brest, Bron, Lille, Lyon, Montpellier, Nice, Paris, Pessac
2024-09-23
Active, closed
Cerevance
Phase 3
330
Bron, Toulouse, Montpellier, Lille, Créteil
2024-09-20
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
160
Brest, Lille, Paris
2024-09-20
Recruiting
European Registry of Next Generation Imaging in Advanced Prostate Cancer
NCT06866782Prostate Cancer, Advanced Prostate Cancer, Metastatic Prostate Cancer (mPC)
Fundacio Puigvert
Observational
600
Lille, Lyon, Paris
2024-09-17
Active, closed
Novo Nordisk A/S
Phase 4
500
Lille, Nice, Paris, Rouen, Toulouse
2024-09-17
Active, closed
Hoffmann-La Roche
Phase 3
400
Amiens, Dijon, La Roche-sur-Yon, Lille, Marseille, Neuilly-sur-Seine, Nice, Pessac
2024-09-17
Recruiting
University Hospital, Limoges
Not applicable
1,000
Lille, Limoges, Marseille, Montpellier, Nice, Paris, Tours
2024-09-17
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
130
Bron, Lille, Paris
2024-09-11
Recruiting
GlaxoSmithKline
Phase 3
440
Angers, Le Kremlin-Bicêtre, Lille, Pessac, Rouen, Toulouse
2024-09-11
Active, closed
Evaluation of the Effect of Lomitapide Treatment on Major Adverse Cardiovascular Events (MACE) in Patients With Homozygous Familial Hypercholesterolemia
NCT06832371Homozygous Familial Hypercholesterolemia (HoFH), Major Adverse Cardiovascular Events (MACE), Dyslipidemia
Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)
Observational
73
Lille, Lyon, Marseille, Paris, Strasbourg
2024-09-09
Recruiting
Gossamer Bio USA, Inc.
Phase 3
330
Le Kremlin-Bicêtre, Lille, Nice, Poitiers
2024-09-03
Not yet open
Hospices Civils de Lyon
Phase 2
70
Bordeaux, Bron, Clermont-Ferrand, Grenoble, Lille, Lyon, Paris, Pierre-Bénite
2024-09-01
Not yet open
The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.
NCT06295094Gastric Cancer, Chemotherapy, Adjuvant, Peritoneal Metastases, Minimally Invasive Surgical Procedures
DrugsDoxorubicin·Cisplatin
Odense University Hospital
Phase 2
264
Lille
2024-09
Active, closed
Servier Bio-Innovation LLC
Phase 1/2
48
Bordeaux, Dijon, Lille, Saint-Cloud, Saint-Herblain, Vandœuvre-lès-Nancy
2024-08-31
Active, closed
Celgene
Phase 2
95
Saint-Cloud, Lille, Poitiers, Paris
2024-08-30
Active, closed
Microbiotica Ltd
Phase 1
41
Dijon, Lille, Lyon, Marseille, Pierre-Bénite
2024-08-28
Recruiting
Bayer
Phase 3
444
La Tronche, Pierre-Bénite, Brest, Mulhouse, Lille, Bordeaux, Limoges, Rouen
2024-08-28
Recruiting
Study of the Pathophysiology of RNU4ATAC and RTTN Associated Syndromes
NCT06111950Taybi Linder Syndrome, Microcephalic Osteodysplastic Primordial Dwarfism Types I and III, Roifman Syndrome, Lowry Wood Syndrome
Hospices Civils de Lyon
Not applicable
45
Bordeaux, Bron, Dijon, Lille, Paris, Rennes
2024-08-27
Recruiting
EDAP TMS S.A.
Not applicable
100
Besançon, Bordeaux, Lille, Lyon, Martigues, Suresnes, Toulon, Toulouse
2024-08-23
Active, closed
Kite, A Gilead Company
Phase 3
452
Lille, Marseille, Montpellier, Nantes, Paris, Pierre-Bénite, Poitiers, Rennes
2024-08-23
Recruiting
Sanofi
Phase 3
160
Le Kremlin-Bicêtre, Lille, Marseille, Nice, Paris
2024-08-21
Recruiting
Jazz Pharmaceuticals
Phase 3
550
Bordeaux, Caen, Dijon, Le Mans, Lille, Marseille, Montpellier, Strasbourg
2024-08-13
Active, closed
Genmab
Phase 3
379
Strasbourg, Caen, Tours, Avignon, Bayonne, Poitiers, Lille
2024-08-13
Recruiting
AstraZeneca
Phase 3
620
Brest, Clichy, Dijon, Lille, Lyon, Marseille, Montpellier, Pessac
2024-08-12
Recruiting
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT06445972Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
DrugsPatritumab deruxtecan·Ramucirumab·Sacituzumab tirumotecan·Paclitaxel
Merck Sharp & Dohme LLC
Phase 1/2
210
Brest, Lille, Paris
2024-08-07
Active, closed
Pfizer
Observational
450
Bordeaux, Argenteuil, Caen, Dijon, La Tronche, Lille, Rennes, Rouen
2024-08-07
Recruiting
AstraZeneca
Phase 3
1,018
Bayonne, La Tronche, Lille, Montpellier, Saint-Cloud, Vandœuvre-lès-Nancy
2024-08-07
Recruiting
AstraZeneca
Phase 3
788
Angers, Besançon, Lille, Lyon, Marseille, Paris, Rouen, Saint-Herblain
2024-08-01
Recruiting
Lallemand Health Solutions
Phase 2
70
Bécon-les-Granits, Boulogne-sur-Mer, Caen, La Tronche, Lille, Montauban, Nantes, Paris
2024-08
Active, closed
Astellas Pharma Global Development, Inc.
Phase 3
982
Angers, Bayonne, Bordeaux, Caen, Dijon, Le Mans, Lille, Lyon
2024-07-31
Recruiting
Hospices Civils de Lyon
Phase 4
140
Avignon, Bobigny, Créteil, Dijon, Lille, Limoges, Lyon, Montpellier
2024-07-30
By invitation
Biohaven Therapeutics Ltd.
Phase 2
660
Strasbourg, Dijon, Toulouse, Montpellier, Tours, Nancy, Lille, Lyon
2024-07-30
Recruiting
Hospices Civils de Lyon
Not applicable
60
Bron, Brest, Garche, Lille, Marseille, Paris, Strasbourg, Toulouse
2024-07-24
Active, closed
Janssen Pharmaceutica N.V., Belgium
Phase 2
55
Lille, Nantes, Paris, Toulouse, Tours
2024-07-22
Recruiting
Daiichi Sankyo
Phase 1/2
123
Lille, Lyon, Marseille, Paris, Rennes, Saint-Herblain, Suresnes, Villejuif
2024-07-22
Recruiting
University Hospital, Lille
Phase 1/2
21
Lille
2024-07-16
Active, closed
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
109
Le Kremlin-Bicêtre, Lille, Marseille, Montpellier, Paris
2024-07-12
Recruiting
Replimune, Inc.
Phase 3
400
Bordeaux, Lille, Marseille, Nice, Paris, Pierre-Bénite, Villejuif
2024-07-11
Recruiting
BIOlogics in Severe Nasal POlyposis SurvEy.: a French Registry
NCT06501807Rhinosinusitis Chronic, Nasal Polyps
University Hospital, Lille
Not applicable
900
Lille
2024-07-11
Active, closed
Assistance Publique - Hôpitaux de Paris
Phase 1/2
25
Bordeaux, Créteil, Lille, Rennes, Tours, Villejuif
2024-07-10
Recruiting
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens
NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
DrugIvosidenib
Servier Bio-Innovation LLC
Phase 3
156
Bordeaux, Lille, Lyon, Marseille, Paris, Saint-Herblain, Strasbourg, Toulouse
2024-07-09
Recruiting
Fundacion Oncosur
Phase 2
78
Bordeaux, Brest, Lille, Paris, Strasbourg, Villejuif
2024-07-05
Active, closed
Transorb™ Self-Gripping Resorbable Mesh in High-risk Subjects Undergoing Open Repair of Ventral Hernia
NCT06449378Hernia, Hernia, Ventral, Hernia, Abdominal, Hernia Abdominal Wall
Medtronic - MITG
Not applicable
163
Colombes, Lille, Lyon, Reims, Rouen, Strasbourg
2024-07-02
Active, closed
Nantes University Hospital
Phase 2
103
Bayonne, Caen, Dijon, La Roche-sur-Yon, Lille, Limoges, Lyon, Marseille
2024-06-26
Active, closed
Novo Nordisk A/S
Phase 3
10,000
Besançon, Bron, Caen, Chambray-lès-Tours, Corbeil-Essonnes, Grenoble, Le Coudray, Lille
2024-06-25
Active, closed
Merus B.V.
Phase 3
621
Bordeaux, Brest, Le Mans, Lille, Lyon, Marseille, Montpellier, Nice
2024-06-25
Recruiting
GERCOR - Multidisciplinary Oncology Cooperative Group
Not applicable
72
Dijon, Grenoble, Lille, Marseille, Reims, Rouen, Saint-Cloud, Saint-Herblain
2024-06-24
Recruiting
AstraZeneca
Phase 3
240
Angers, Brest, Le Mans, Lille, Lyon, Paris, Reims, Rouen
2024-06-20
Active, closed
H. Lundbeck A/S
Phase 2
16
Bron, Lille, Pessac, Angers, Marseille, Le Kremlin-Bicêtre
2024-06-19
Recruiting
Orthofix s.r.l.
Observational
45
Saint-Etienne, Strasbourg, Lille, Toulouse, Marseille
2024-06-18
Recruiting
Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse
NCT06271057Diffuse Large B-cell Lymphoma Refractory, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory High Grade B-Cell Lymphoma
DrugGolcadomide
The Lymphoma Academic Research Organisation
Phase 2
65
Créteil, Dijon, La Tronche, Lille, Marseille, Montpellier, Nantes, Paris
2024-06-14
Active, closed
Janssen Research & Development, LLC
Phase 1
108
Lille, Lyon, Nantes, Pessac
2024-06-07
Recruiting
University Hospital, Lille
Not applicable
72
Lille
2024-06-06
Recruiting
Immunocore Ltd
Phase 3
680
Marseille, Toulouse, Bobigny, Boulogne-Billancourt, Caen, Dijon, Lille, Nantes
2024-06-05
Recruiting
Eli Lilly and Company
Phase 3
300
Angers, Bron, Lille, Marseille, Paris, Toulouse
2024-06-03
Recruiting
Kartos Therapeutics, Inc.
Phase 3
600
Paris, Amiens, Angers, Lille, Lyon, Nantes, Nice, Nîmes
2024-06-03
Not yet open
Validation of a Prognostic Score for Steroid Therapy Response in Acute Severe Autoimmune Hepatitis
NCT05473403Liver Failure, Acute, Hepatitis, Autoimmune, Organ Dysfunction Scores, Risk Factors
Assistance Publique - Hôpitaux de Paris
Not applicable
150
Angers, Besançon, Bobigny, Brest, Caen, Chambray-lès-Tours, Dijon, Lille
2024-06-01
Recruiting
Centre Oscar Lambret
Not applicable
377
Lyon, Besançon, Rennes, Strasbourg, Lille, Poitiers, Toulouse, Saint-Herblain
2024-05-29
Recruiting
Institut Curie
Phase 3
300
Bayonne, Bordeaux, Caen, Dijon, Lille, Limoges, Lyon, Marseille
2024-05-27
Recruiting
University Hospital, Lille
Observational
165
Lille
2024-05-27
Recruiting
Aptissen SA
Not applicable
70
Belfort, Dunkirk, Lille
2024-05-27
Recruiting
Impact of Environmental Exposures on Tumor Risk in SDHx-mutation Carriers
NCT06408402SDH-Related Familial Paraganglioma, SDHx-Related Syndromes, SDH Gene Mutation, Environmental Exposure
Assistance Publique - Hôpitaux de Paris
Observational
1,300
Angers, Besançon, Bron, Caen, Grenoble, Lille, Marseille, Montpellier
2024-05-22
Recruiting
Daiichi Sankyo
Phase 3
540
Avignon, Bordeaux, Créteil, Lille, Limoges, Lyon, Marseille, Montpellier
2024-05-21
Recruiting
University Hospital, Angers
Not applicable
120
Angers, Lille, Lyon, Marseille, Nancy, Paris, Rennes
2024-05-15
Not yet open
Lille Catholic University
Not applicable
63
Arras, Lille, Lomme, Roubaix
2024-05-15
Rows per page Showing 1–500 of 1281
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a French investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 October 2026. https://priyalifescience.com/clinical-trials-france/city/lille

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in France and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,722 studies in total at the last sync on 29 Oct 2026, 03:20 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,281 of those studies with a site in Lille.

How many clinical trials are recruiting in Lille?

713 of the 1,281 studies on this page are recruiting new participants as of the 29 Oct 2026, 03:20 UTC sync. A further 89 have not yet opened recruitment, 463 are active but closed to new participants, and 16 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Lille), 1,281 studies
PhaseStudiesRecruitingShare
Phase 340018631.2%
Not applicable26917621%
Observational24216518.9%
Phase 21767613.7%
Phase 1/286486.7%
Phase 143213.4%
Phase 2/341253.2%
Phase 424161.9%

Most active sponsors

Lead sponsors with the most studies (Lille)
Lead sponsorStudiesRecruiting
University Hospital, Lille138111
Janssen Research & Development, LLC4318
Hoffmann-La Roche3811
AstraZeneca3616
Assistance Publique - Hôpitaux de Paris3423
Hospices Civils de Lyon3420
Novartis Pharmaceuticals3111
Bristol-Myers Squibb2314
Merck Sharp & Dohme LLC2313
Sanofi2310
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.